Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
HIGH-DOSE ETOPOSIDE, CYCLOPHOSPHAMIDE, AND TOTAL-BODY IRRADIATION WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID-LEUKEMIA IN UNTREATED FIRST RELAPSE - A STUDY BY THE NORTH-AMERICANMARROW TRANSPLANT GROUP
Autore:
BROWN RA; WOLFF SN; FAY JW; PINEIRO L; COLLINS RH; LYNCH JP; STEVENS D; GREER J; HERZIG RH; HERZIG GP;
Indirizzi:
WOHL HOSP,BARNARD CANC CTR,3RD FLOOR,4960 CHILDRENS PL ST LOUIS MO 63110 WASHINGTON UNIV,DIV BONE MARROW TRANSPLANTAT & STEM CELL BIOL ST LOUIS MO 00000 VANDERBILT UNIV,DEPT MED NASHVILLE TN 00000 BAYLOR UNIV,MED CTR DALLAS TX 00000 W VIRGINIA UNIV,DEPT MED MORGANTOWN WV 00000 UNIV LOUISVILLE LOUISVILLE KY 00000 ROSWELL PK CANC INST,DEPT MED BUFFALO NY 00000
Titolo Testata:
Blood
fascicolo: 5, volume: 85, anno: 1995,
pagine: 1391 - 1395
SICI:
0006-4971(1995)85:5<1391:HECATI>2.0.ZU;2-C
Fonte:
ISI
Lingua:
ENG
Soggetto:
VERSUS-HOST DISEASE; 1ST REMISSION; HEMATOLOGICAL MALIGNANCIES; PREPARATORY REGIMEN; PHASE-I; BUSULFAN; GRAFT; THERAPY; CYTARABINE; INFUSION;
Tipo documento:
Article
Natura:
Periodico
Settore Disciplinare:
Science Citation Index Expanded
Citazioni:
30
Recensione:
Indirizzi per estratti:
Citazione:
R.A. Brown et al., "HIGH-DOSE ETOPOSIDE, CYCLOPHOSPHAMIDE, AND TOTAL-BODY IRRADIATION WITH ALLOGENEIC BONE-MARROW TRANSPLANTATION FOR PATIENTS WITH ACUTE MYELOID-LEUKEMIA IN UNTREATED FIRST RELAPSE - A STUDY BY THE NORTH-AMERICANMARROW TRANSPLANT GROUP", Blood, 85(5), 1995, pp. 1391-1395

Abstract

Relapse is a major cause of treatment failure following allogeneic bone marrow transplantation (BMT) for acute myeloid leukemia (AML). To reduce the risk of relapse following BMT for patients with hematologic malignancy, our group developed a novel preparative regimen which combines high-dose etoposide with cyclophosphamide and total body irradiation (VPCyTBI). We now report the outcome of therapy with VPCyTBI followed by allogeneic BMT for 40 patients with AML in untreated first relapse. With the exception of increased stomatitis, the toxicity of this regimen was similar to that reported by others for CyTBI. Forty-four months after transplant the actuarial probabilities of disease-free survival (DFS), persistent or recurrent leukemia, and transplant related mortality were .29, .44, and.47 respectively. DFS was improved (P < .01) and risk of persistent or recurrent leukemia reduced (P = .005) among patients with significant (grade greater than or equal to 2) acute GVHD. Patients with 30% or more blasts on pre-BMT bone marrow examination were not at increased risk for persistent or recurrent leukemia. We conclude that VPCyTBI with allogeneic BMT is effective therapy for AML in untreated first relapse and that a randomized trial comparing this regimen with CyTBI is warranted. (C) 1995 by The American Society of Hematology.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 15/07/20 alle ore 21:29:23